Scribe Therapeutics Funding & Investors
Scribe is focused on the engineering, delivery, and development of next-generation CRISPR molecules to rewrite and repair the underlying cause of genetic disorders.
scribetx.comTotal Amount Raised: $120,000,000
Scribe Therapeutics Funding Rounds
Series B
$100,000,000
Series B Investors
Avoro Capital Advisors (formerly venBio Select Advisor)Avoro VenturesMenlo VenturesRa Capital ManagementOrbiMed AdvisorsPerceptive AdvisorsAndreessen HorowitzT. Rowe PriceWellington ManagementSeries A
$20,000,000
Series A Investors
Andreessen Horowitz
Funding info provided by Diffbot.